ArticleEuropean journal of medical research2025
Integrated bulk and single-cell transcriptomics to develop an efferocytosis-related prognostic model for lung adenocarcinoma and validate the key gene LDHA.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEfferocytosis, the phagocytic clearance of apoptotic cells, exerts dual anti-inflammatory and pro-tumorigenic effects, while existing studies have not well-elucidated the underlying mechanisms in Lung adenocarcinoma (LUAD). This study aims at identifying prognostic genes related to efferocytosis and potential therapeutic targets in LUAD.
methodsLUAD-related gene expression data sets were obtained from UCSC Xena and GEO databases, while efferocytosis-related genes (ERGs) were sourced from the GeneCards database. Unsupervised consensus clustering analysis assisted in classifying LUAD patients into two distinct subgroups, after which differential gene expression was analyzed for identifying differentially expressed genes (DEGs). Subsequently, a four-gene prognostic model was built by virtue of LASSO-Cox regression and further validated by Kaplan-Meier (KM) analysis and receiver operating characteristic (ROC) curve assessment. Analysis on single-cell RNA sequencing (scRNA-seq) data engaged in investigating cell subpopulations associated with efferocytosis and to pinpoint key genes involved. In vitro experiments were conducted to ascertain the functional importance of the selected key gene in LUAD progression.
resultsA prognostic signature incorporating four genes was successfully constructed for LUAD, and risk scores were calculated for categorizing patients into low- and high-risk groups. Notably, the two risk groups presented different survival outcomes and immune cell infiltration (ICI). Analysis of scRNA-seq data revealed macrophages as the primary efferocytosis-related cell type in LUAD and pinpointed LDHA as a key regulatory gene. Pseudotime trajectory analysis demonstrated a progressive increase in LDHA expression and efferocytosis-related activity as macrophages differentiated into tumor-associated macrophages (TAMs). Moreover, in vitro experimental data showed that LDHA silencing in macrophages facilitated polarization toward an M1 phenotype and simultaneously inhibited M2 polarization. In addition, co-culturing LUAD cells with LDHA-silenced M2 macrophages substantially reduced cancer cell proliferation, migration, and invasion. Cell communication analyses suggested that LDHA promotes M2-type TAMs by modulating the SPP1 pathway between macrophages and cancer-associated fibroblasts (CAFs), activating ECM receptors and downstream effectors.
conclusionsWe constructed an efferocytosis-related prognostic gene model for LUAD. Furthermore, LDHA may target M2 macrophages, highlighting its potential as a therapeutic target in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.